Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
Senior living residents contribute to understanding of aging through pilot studies despite pandemic challenges
By
Kimberly Bonvissuto
Dec 14, 2020
Senior living residents are furthering the understanding of aging through pilot programs in their communities even while they cope with the effects of a global pandemic.
Special needs
By
Julie E. Williamson
Mar 01, 2018
Residents with cognitive impairment present unique challenges and opportunities for the senior living field.